Ausgabe 2/2016
Inhalt (15 Artikel)
Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549
Izabella Thaís Silva, Fabiana Cristina Geller, Lara Persich, Sabine Eva Dudek, Karen Luise Lang, Miguel Soriano Balparda Caro, Fernando Javier Durán, Eloir Paulo Schenkel, Stephan Ludwig, Cláudia Maria Oliveira Simões
Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats
Xuhui Bao, Vidyalakshmi Chandramohan, Randall P. Reynolds, John N. Norton, William C. Wetsel, Ramona M. Rodriguiz, Dipendra K. Aryal, Roger E. McLendon, Edward D. Levin, Neil A. Petry, Michael R. Zalutsky, Bruce K. Burnett, Chien-Tsun Kuan, Ira H. Pastan, Darell D. Bigner
The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15
Paula Kinsella, Lisa M. Greene, Sandra A. Bright, Jade K. Pollock, Stefania Butini, Giuseppe Campiani, Sebastian Bauer, D. Clive Williams, Daniela M. Zisterer
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer
Dustin A. Deming, Ludmila L. Cavalcante, Sam J. Lubner, Daniel L. Mulkerin, Noelle K. LoConte, Jens C. Eickhoff, Jill M. Kolesar, Suzanne Fioravanti, Tim F. Greten, Kathryn Compton, Austin G. Doyle, George Wilding, Austin Duffy, Glenn Liu
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers
Elizabeth R. Kessler, S. Gail Eckhardt, Todd M. Pitts, Erica L. Bradshaw-Pierce, Cindy L. O’byrant, Wells A. Messersmith, Sujatha Nallapreddy, Colin Weekes, Jennifer Spratlin, Christopher H. Lieu, Madeleine A. Kane, Sarah Eppers, Elizabeth Freas, Stephen Leong
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies
Geert A. Cirkel, Bojana Milojkovic Kerklaan, Frédéric Vanhoutte, Annegret Van der Aa, Giocondo Lorenzon, Florence Namour, Philippe Pujuguet, Sophie Darquenne, Filip Y. F. de Vos, Tom J. Snijders, Emile E. Voest, Jan H. M. Schellens, Martijn P. Lolkema
Pharmacokinetics, metabolism, and excretion of 14C-labeled belinostat in patients with recurrent or progressive malignancies
Emiliano Calvo, Guru Reddy, Valentina Boni, Lina García-Cañamaque, Tao Song, Jette Tjornelund, Mi Rim Choi, Lee F. Allen
Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects
C. E. Halstenson, T. Shamp, M. A. Gargano, R. M. Walsh, M. L. Patchen
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
Jeffrey R. Infante, David S. Mendelson, Howard A. Burris III, Johanna C. Bendell, Anthony W. Tolcher, Michael S. Gordon, Heidi H. Gillenwater, Shirin Arastu-Kapur, Hansen L. Wong, Kyriakos P. Papadopoulos
A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer
Christos E. Kyriakopoulos, Elisabeth I. Heath, Jens C. Eickhoff, Jill Kolesar, Mulusew Yayehyirad, Thomas Moll, George Wilding, Glenn Liu
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma
Elaine McWhirter, Ian Quirt, Thomas Gajewski, Gregory Pond, Lisa Wang, June Hui, Amit Oza
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
Andrea Necchi, Salvatore Lo Vullo, Luigi Mariani, Daniele Raggi, Patrizia Giannatempo, Giuseppina Calareso, Elena Togliardi, Flavio Crippa, Nicola Di Genova, Federica Perrone, Maurizio Colecchia, Biagio Paolini, Giuseppe Pelosi, Nicola Nicolai, Giuseppe Procopio, Roberto Salvioni, Filippo G. De Braud
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation
Sumati Gupta, Launce Gouw, Jennifer Wright, Sant Chawla, Debbie Pitt, Mark Wade, Ken Boucher, Sunil Sharma
Targeting BRAF mutants in clear-cell sarcomas of soft tissue: beyond sarcoma or melanoma classification
Arnaud Uguen, Pascale Marcorelles, Marc De Braekeleer
Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib
Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Eiichiro Suzuki, Naoya Kanogawa, Tomoko Saito, Tenyu Motoyama, Akinobu Tawada, Fumihiko Kanai, Osamu Yokosuka